simendan has been researched along with Apoplexy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleilevens, C; Bruells, C; Hein, M; Roehl, AB; Rossaint, R; Zoremba, N | 1 |
| Gröhn, O; Haapalinna, A; Haasio, K; Hyttilä-Hopponen, M; Kivikko, M; Kuoppamäki, M; Levijoki, J; Miettinen, R; Pollesello, P; Puoliväli, J; Sallinen, J; Tähtivaara, L; Yrjänheikki, J | 1 |
2 other study(ies) available for simendan and Apoplexy
| Article | Year |
|---|---|
Levosimendan limits reperfusion injury in a rat middle cerebral artery occlusion (MCAO) model.
Topics: Animals; Blood Pressure; Brain Ischemia; Cerebrovascular Circulation; Hydrazones; Infarction, Middle Cerebral Artery; Male; Pyridazines; Rats; Rats, Wistar; Reperfusion Injury; Simendan; Stroke; Tumor Necrosis Factor-alpha | 2013 |
Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats.
Topics: Animals; Blood Pressure; Blood Volume; Brain; Drug Interactions; Hydrazones; Male; Pyridazines; Rats; Rats, Inbred Dahl; Simendan; Stroke; Valsartan; Vasodilator Agents | 2015 |